Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
During the BBC's election night coverage, Jeremy Paxman asked Galloway about whether he was happy to have removed one of the few black women in parliament, He replied: "I don't believe that people get elected because of the colour of their skin. I believe that people get elected because of their record and because of their policies". Oona King later told BBC Radio 4's Today programme that she found Paxman's line of questioning inappropriate. Galloway "shouldn't be barred from running against me because I'm a black woman. ... I was not defined, or did not wish to be defined, by either my ethnicity or religious background".
Red yeast rice is used to color a wide variety of food products, including fermented tofu, red rice vinegar, char siu, Peking duck, and Chinese pastries that require red food coloring. In China, documentation dates back to at least the first century CE. It is also traditionally used in the production of several types of Chinese huangjiu (Shaoxing jiu), and Japanese sake (akaisake), imparting a reddish color to these wines. It was called a "koji" in Japanese, meaning "grain or bean overgrown with a mold culture". The lees left over from wine production, known as hóngzāo (红糟), can be used as flavoring, imparting a subtle but pleasant taste to food. The lees are particularly commonly used in Fujian cuisine, where they are used for dishes like Fujian red wine chicken, a celebratory dish associated with birthdays and Chinese New Year. Red yeast rice (angkák in Filipino) is also used widely in the Philippines to traditionally color and preserve certain dishes like fermented shrimp (bagoóng alamáng), burong isdâ (fermented rice and fish), and balao-balao (fermented rice and shrimp).
In late 1991, Fripp asked former Japan singer David Sylvian to join a new King Crimson line-up. Sylvian declined the offer, but agreed to work with Fripp on a collaborative album; the resulting album The First Day was issued in 1993 under the name Sylvian/Fripp. In June 1993, Fripp began to assemble a larger version of King Crimson featuring Belew and Levin, Chapman Stick player Trey Gunn (a veteran of Fripp's Guitar Craft courses and a session musician on The First Day) and drummer Jerry Marotta, with whom Fripp and Levin had played in Peter Gabriel's band. After Sylvian/Fripp's closing concerts at the Royal Albert Hall in December 1993, Fripp decided to ask the tour's drummer Pat Mastelotto, formerly of Mr. Mister, to join instead of Marotta. Bruford would become the last member of the 1980s quartet to return to the band. Bruford later said he had lobbied Fripp at the last minute because he believed that Crimson was still very much "his gig", and that Fripp had come up with a philosophical explanation for utilizing both Mastelotto and Bruford later. One of the conditions Fripp imposed upon Bruford if he were to return was to give up all creative control to Fripp. Fripp later explained that he had a vision of a "Double Trio" with two guitarists, two bassists, and two drummers while driving along the Chalke Valley in Wiltshire one afternoon in 1992. Following rehearsals in Woodstock, New York, the group released the EP Vrooom in October 1994.
=== Electrical === In electrical FFF a transverse electrical current (DC) is applied which creates an electric field. Depending on the charge of sample components, an electrophoretic drift velocity is induced, counteracted by the diffusion from Brownian motion, so the separation depends on the ratio of electrophoretic mobility and size. Application of electrical FFF has been limited and is currently rarely used. Other modifications have been developed, namely cyclical electrical FFF where a special alternating current is applied. It allows to separate according to electrophoretic mobility. Another variation is electrical asymmetrical flow FFF (EAF4), where an electrical field is applied in addition to a cross flow field. EAF4 overcomes the limitation of pure electrical FFF which has poor resolution and suffers from electrolysis products and bubbles contaminating the channel outflow and compromising the detector signals.
The basic components of a mature mammary gland are the alveoli (hollow cavities, a few millimeters large), which are lined with milk-secreting cuboidal cells and surrounded by myoepithelial cells. These alveoli join to form groups known as lobules. Each lobule has a lactiferous duct that drains into openings in the nipple. The myoepithelial cells contract under the stimulation of oxytocin, excreting the milk secreted by alveolar units into the lobule lumen toward the nipple. As the infant begins to suck, the oxytocin-mediated "let down reflex" ensues, and the mother's milk is secreted—not sucked—from the gland into the infant's mouth. All the milk-secreting tissue leading to a single lactiferous duct is collectively called a "simple mammary gland"; in a "complex mammary gland", all the simple mammary glands serve one nipple. Humans normally have two complex mammary glands, one in each breast, and each complex mammary gland consists of 10–20 simple glands. The opening of each simple gland on the surface of the nipple is called a "pore." The presence of more than two nipples is known as polythelia and the presence of more than two complex mammary glands as polymastia. Maintaining the correct polarized morphology of the lactiferous duct tree requires another essential component – mammary epithelial cells extracellular matrix (ECM) which, together with adipocytes, fibroblast, inflammatory cells, and others, constitute mammary stroma. Mammary epithelial ECM mainly contains myoepithelial basement membrane and the connective tissue.
Sources: en.wikipedia.org
As a result of population growth in African-Caribbean regions of overseas France and immigration from North and sub-Saharan Africa to mainland France, sickle cell disease has become a major health problem in France. Sickle cell disease has become the most common genetic disease in the country, with an overall birth prevalence of one in 2,415 in mainland France, ahead of phenylketonuria (one in 10,862), congenital hypothyroidism (one in 3,132), congenital adrenal hyperplasia (one in 19,008) and cystic fibrosis (one in 5,014) for the same reference period.
Kurtzer Natalia Mehlman Petrzela (2000), professor of history at The New School Fotini Christia (2001), Greek political scientist, professor at Massachusetts Institute of Technology Joya Powell (2001), Bessie Awards-winning choreographer and educator Agnia Grigas (2002), political scientist and author Cassie Mogilner Holmes (2002), professor at the UCLA Anderson School of Management Daniel Immerwahr (2002), professor of history of Northwestern University and recipient of the Merle Curti Award Jessica Chiccehitto Hindman (2003), professor at Northern Kentucky University, National Book Critics Circle Award finalist Rujeko Hockley (2005), curator of the Whitney Museum of American Art and the 2019 Whitney Biennial Susanna Berger (2007), art historian, professor at University of Southern California Ashley James (2009), first black curator of the Solomon R. Guggenheim Museum
Phlebotomies are carried out by phlebotomists – people trained to draw blood mostly from veins for clinical or medical testing, transfusions, donations, or research. Blood is collected primarily by performing venipunctures, or by using capillary blood sampling with fingersticks or a heel stick in infants for the collection of minute quantities of blood. The duties of a phlebotomist may include interpreting the tests requested, drawing blood into the correct tubes with the proper additives, accurately explaining the procedure to the person and preparing them accordingly, practicing the required forms of asepsis, practicing standard and universal precautions, restoring hemostasis of the puncture site, giving instructions on post-puncture care, affixing tubes with electronically printed labels, and delivering specimens to a laboratory. Some countries, states, or districts require that phlebotomists be licensed or registered. A therapeutic phlebotomy may be carried out in the treatment of some blood disorders (examples: hemochromatosis, polycythemia vera, porphyria cutanea tarda), and chronic hives (in research).
==== Never marketed ==== 4′-Fluorococaine (also a Dopamine reuptake inhibitor) Delucemine (also an NMDA antagonist) Mesembrenone (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Mesembrine (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Roxindole (EMD-49,980) (also a 5-HT1A and D2-like receptor agonist)
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.